Reviewed by the PeptideMind Team · Updated July 29, 2026
Tesamorelin vs CJC-1295:
Key differences comparison
The main difference between Tesamorelin and CJC-1295 is regulatory status and duration. Tesamorelin is FDA-approved for visceral fat reduction and needs a daily injection, since it clears the body in about 30 minutes. CJC-1295 (with DAC) is an unapproved research peptide that binds to a blood protein, extending its effect to about a week so it's typically injected only once or twice weekly.
Weight
tesa
Growth
VS
Growth
cjc1
Growth
As seen on
What Is Tesamorelin?
Tesamorelin (brand name Egrifta) is a lab-made copy of a hormone your body already makes to trigger growth hormone release. It's FDA-approved specifically to reduce visceral fat, the deep fat that surrounds your organs, in people with HIV-related fat redistribution, and it's also studied off-label for general fat loss and body composition.
How it works
Tesamorelin attaches to the same pituitary receptor as your body's natural GHRH, prompting a short, controlled burst of growth hormone that clears from the body in about 30 minutes.
What it's best known for
Reducing visceral fat, the deep abdominal fat tied to metabolic risk. Clinical trials showed meaningful visceral fat reductions along with improved triglycerides and liver fat.
Where it stands legally
The branded version, Egrifta, is FDA-approved for HIV-associated lipodystrophy. Research-grade tesamorelin sold online is not approved for human use and is labeled for research only.
What Is CJC-1295?
CJC-1295 is a lab-made version of the same natural hormone, modified with a chemical tag called DAC that lets it latch onto a protein already circulating in your blood. That tag is what stretches its effects from minutes to nearly a week, which is why it's typically injected only once or twice weekly instead of daily.
A longer-lasting design
The DAC tag lets CJC-1295 bind to albumin, a protein always present in blood, turning it into a slow-release depot that keeps growth hormone elevated for days instead of minutes.
What it's best known for
Sustained growth hormone and IGF-1 elevation for muscle building, recovery, and body composition goals, often studied alongside a companion peptide like Ipamorelin.
Where it stands legally
CJC-1295 has no FDA approval for any use. It's sold online strictly as an unregulated research chemical, not intended for people to use on themselves.
Tesamorelin vs CJC-1295 at a Glance
A side-by-side look at how Tesamorelin and CJC-1295 differ in how they work, how they're dosed, and where each stands legally.
Overview
- Type
- Single peptide
- Primary category
- Weight
- Secondary categories
- Growth
- Research status
- Fda Approved
- FDA approved
- FDA approved
- Popularity
- 8/10
- Body targets
- HormonesMetabolic
- Price range
- $30.00 – $207.50
- Human trial status
- FDA approved
- Legal status
- FDA-approved drug
- WADA status
- Banned
Dosing
- Dose
- 0.5mg–2 mg
- Frequency
- 5 days on / 2 days off
- Cycle
- 8–12 weeks
- Route of administration
- Subcutaneous
- Common vial sizes
- 2mg5mg+1
Research
- Molecular weight
- 5135.86 g/mol
- Half-life
- 0.5 hrs
- Median onset
- —
- Prescription alternative
- Has alternative
- Receptor target
- GHRHR
- Receptor action
- Agonist
- Mechanistic pathways
- GHRH GH AXIS
Included in
Overview
- Type
- Single peptide
- Primary category
- Growth
- Secondary categories
- Weight
- Research status
- Phase 2
- FDA approved
- Not FDA approved
- Popularity
- 5/10
- Body targets
- HormonesMuscle
- Price range
- Human trial status
- Human RCTs
- Legal status
- Research chemical
- WADA status
- Banned
Dosing
- Dose
- 1–2 mg
- Frequency
- Weekly
- Cycle
- 8–12 weeks
- Route of administration
- Subcutaneous
- Common vial sizes
- 2mg5mg
Research
- Molecular weight
- 3647.25 g/mol
- Half-life
- 168 hrs
- Median onset
- —
- Prescription alternative
- Has alternative
- Receptor target
- GHRHR
- Receptor action
- Agonist
- Mechanistic pathways
- GHRH GH AXIS
Included in
Our top-rated vendor
Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing,, no paid placements, no affiliate influence. We update this list as new data comes in.
Based on current scores, this vendor ranks highest across those criteria.
#1 Rated Research Peptide Supplier
Comparison at a Glance: Tesamorelin vs CJC-1295
A quick side-by-side look at how Tesamorelin and CJC-1295 differ in how growth hormone is released, what the trial evidence shows, and where each stands legally.
How growth hormone is released
Tesamorelin's short half-life produces one clean pulse of growth hormone per dose, closely matching the body's natural rhythm. CJC-1295's DAC tag keeps levels elevated continuously for days, trading that pulsatile pattern for convenience.
Visceral fat evidence
Tesamorelin has FDA trial data behind it, showing meaningful reductions in visceral fat, triglycerides, and liver fat. CJC-1295 has been studied for similar effects, but without the same level of approved clinical evidence.
Dosing frequency
Tesamorelin is injected once daily. CJC-1295 (with DAC) is injected once or twice a week thanks to its longer half-life, which is the main convenience trade-off between the two.
Legal status
Tesamorelin's branded version, Egrifta, is FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. CJC-1295 has no FDA approval for any use and is sold strictly as a research chemical.
Tesamorelin vs CJC-1295: Which One Should You Research?
Because both act on the same GHRH receptor, Tesamorelin and CJC-1295 are rarely combined at full doses since their effects overlap. The choice usually comes down to whether the research calls for an FDA-backed, pulsatile option or a longer-acting research compound.
If visceral fat reduction with trial backing is the priority
Tesamorelin has FDA-approved clinical data specifically for reducing visceral fat, giving it a more established evidence base than CJC-1295 for this particular use.
If dosing convenience matters more
CJC-1295 (with DAC) is reported to sustain growth hormone and IGF-1 elevation for days per dose, cutting injection frequency down to once or twice a week instead of daily.
Neither is approved for anti-aging or bodybuilding use
Only Egrifta, Tesamorelin's branded version, is FDA-approved, and only for visceral fat in HIV-associated lipodystrophy. Research-grade versions of both peptides are sold strictly for research, not for people to use on themselves.
Frequently Asked Questions: Tesamorelin vs CJC-1295
Straight answers on how Tesamorelin and CJC-1295 compare, and how each is dosed. For research reference only.
Tesamorelin vs CJC-1295: Dosing Basics
Both peptides raise growth hormone through the same receptor, but the injection schedule looks very different because of how long each one stays active in the body.
Tesamorelin dosing
The FDA-approved protocol is 2 mg injected once daily under the skin, typically in the abdomen. Off-label research sometimes cycles this 3 months on, 2 months off, though the approved clinical use is continuous.
CJC-1295 (with DAC) dosing
Commonly discussed at 300 to 1,000 mcg per injection, titrated up from a lower starting dose, and given once or twice weekly. Research protocols often run 8 to 12 weeks before a break.
Use a peptide-specific calculator
How concentrated the vial is and how much liquid you mix in changes the actual draw for both peptides. Use a dosage calculator to get an exact number instead of guessing from a general range.
Body Composition Timeline: What to Expect Week by Week
Timelines vary by person, dose, and which peptide is used, but trial data and research write-ups describe a similar general pattern for both.
Weeks 1 to 6
IGF-1 levels begin rising for both peptides within the first two weeks, often alongside improved sleep and energy. Mild joint discomfort or water retention is sometimes reported early on with either compound.
Weeks 8 to 12
Visible visceral fat reduction and a smaller waist circumference are commonly reported with Tesamorelin in this window, while CJC-1295 users often describe noticeable body composition changes building over the same stretch.
Weeks 12 to 26 and beyond
Tesamorelin's clinical trials showed peak visceral fat and body composition improvements around this point with continued daily use. Effects from either peptide fade gradually within weeks of stopping, since neither creates a permanent change.
Free Downloadable Peptide Dosage Cheat Sheets
Reference dosage data for 100+ peptides is pre-loaded in these free cheat sheets, including common research stacks like the wolverine stack (BPC-157 + TB-500), MOTS-C, Retatrutide, and Semaglutide. Select a cheat sheet to see reference dose ranges, dosing frequency, and half-life for every peptide it covers. For research purposes only.
